Nexstim Oy, a Finnish firm, has been approved to market its Navigated Brain Therapy (NBT) System in Europe for treatment of acute depression and as a tool for aiding recovery in post-stroke patients.
The device delivers transcranial magnetic stimulation to target regions of the brain and uses MRI imaging acquired pre-op for guidance.
From the announcement:
The NBT System is the first non-invasive, non-systemic therapeutic device CE-marked to offer patients a personalized treatment for major depression. In addition, the NBT System is CE-marked for use in patients recovering from stroke as a supplement to conventional rehabilitation. The navigation feature of NBT allows for accurately targeting therapy directly to the cortical structures believed to be involved in brain dysfunctions.
Nexstim´s NBT System is unique because its clinically-proven MRI-based navigation allows the user to visualize the electric field inside the patient´s brain and accurately target therapy. Nexstim´s navigation feature eliminates the unscientific “hit and miss” errors inherent in other devices and uniquely enables treatment sessions to be identically replicated for each patient.
In depression, non-invasive, navigated brain therapy has been shown to be safe, well-tolerated and without the side-effects frequently associated with oral antidepressants. A course of therapy with NBT is a painless outpatient procedure and is typically performed in the physician´s office.
Product page: NBS System 4…